Skip to main content

Table 1 Mean percentage of patients achieving PASI 75 response with psoriasis biologic treatments

From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece

Agent

Mean (%)

95% CI

Adalimumab

58

49–68

Etanercept

52

45–59

Infliximab

80

70–87

Ustekinumab

69

62–75

  1. aThe relevant dosing scheme for each product is presented in Table 3.
  2. CI, confidence interval; PASI, Psoriasis Area and Severity Index.
  3. Source: Reich et al., 2012.